Literature DB >> 3156857

Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I.

P C Harpel, T S Chang, E Verderber.   

Abstract

The effect of tissue plasminogen activator (TPA) or urokinase on the specific binding of human Glu-plasminogen to fibrin I formed in plasma by clotting with Reptilase was studied using 125I-plasminogen and 131I-fibrinogen. In the absence of TPA, small amounts of plasminogen were bound to fibrin I. TPA induced binding of plasminogen to plasma fibrin I that was dependent upon the concentrations of TPA and plasminogen as well as upon the time of incubation. Plasminogen binding occurred in association with fibrin clot lysis and the formation in the clot supernatant of alpha 2-plasmin inhibitor-plasmin complexes. Urokinase also induced binding of plasminogen to plasma fibrin I that was concentration- and time-dependent. The molecular form of plasminogen bound to the fibrin I plasma clot was identified as Glu-plasminogen by dodecyl sulfate-polyacrylamide gel electrophoresis and by fast performance liquid chromatography. Further studies demonstrated that fibrin I formed from fibrinogen that had been progressively degraded by plasmin-bound Glu-plasminogen. The mole ratio of plasminogen bound increased with the time of plasmin digestion. Glu-plasminogen did not bind to fibrin I formed from fibrinogen progressively digested by human leukocyte elastase, thereby demonstrating the specificity of plasmin. These studies demonstrate that plasminogen activators regulate the binding of Glu-plasminogen to fibrin I by catalyzing plasmin-mediated modifications in the fibrin substrate.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156857

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Lipoprotein(a): searching for a function.

Authors:  P C Harpel; M Poon; X Zhang; M B Taubman
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

2.  Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.

Authors:  R Pannell; J Black; V Gurewich
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

3.  Inner clot diffusion and permeation during fibrinolysis.

Authors:  S L Diamond; S Anand
Journal:  Biophys J       Date:  1993-12       Impact factor: 4.033

4.  The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.

Authors:  D Rouy; E Anglés-Cano
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

5.  Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.

Authors:  R Pannell; S Li; V Gurewich
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

6.  Plasma carboxypeptidases as regulators of the plasminogen system.

Authors:  A Redlitz; A K Tan; D L Eaton; E F Plow
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

7.  Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

Authors:  J M Edelberg; S V Pizzo
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

8.  Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

Authors:  J H Wu; S L Diamond
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

9.  Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism.

Authors:  P C Harpel; V T Chang; W Borth
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Interaction of histidine-rich glycoprotein with fibrinogen and fibrin.

Authors:  L L Leung
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.